Pharmacogenomics (how genetics affect drug response — e.g., CYP2D6, CYP2C19, TPMT) is a high-value, well-bounded RAG use case: the variant-to-drug-guidance mapping (CPIC guidelines) is structured and citable, and the answers are actionable.
Carrier status, polygenic risk summaries, and ancestry are other slices.
Bounded, guideline-backed domains are great MVP targets because retrieval has authoritative sources and the failure cost is controllable.